Detalles de la búsqueda
1.
Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
J Pharmacokinet Pharmacodyn
; 2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578533
2.
Complex Metabolism of the Novel Neurosteroid, Ganaxolone, in Humans: A Unique Challenge for Metabolites in Safety Testing Assessment.
Drug Metab Dispos
; 51(6): 753-763, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36863866
3.
A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.
Eur Child Adolesc Psychiatry
; 32(3): 491-499, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34581911
4.
The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder.
Br J Clin Pharmacol
; 88(11): 4828-4838, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35588245
5.
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
J Clin Psychopharmacol
; 41(4): 370-380, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34181360
6.
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder.
Int J Clin Pract
; 75(8): e14330, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33971070
7.
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
J Pharmacokinet Pharmacodyn
; 2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38816542
8.
Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree® ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorder.
Brain Behav
; 13(4): e2910, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36847750
9.
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.
Psychiatry Res
; 318: 114922, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36375329
10.
Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials.
Psychiatry Res
; 296: 113664, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33418457
11.
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials.
Neuropsychiatr Dis Treat
; 17: 1751-1762, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34113106
12.
Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.
Paediatr Drugs
; 23(6): 583-589, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34523063
13.
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.
Clin Ther
; 43(4): 684-700, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33750646
14.
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
J Child Adolesc Psychopharmacol
; 31(3): 214-226, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33600233
15.
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.
Psychopharmacol Bull
; 51(2): 43-64, 2021 03 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34092822
16.
Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults.
J Clin Psychiatry
; 81(6)2020 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33049804
17.
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
Clin Ther
; 42(8): 1452-1466, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32723670
18.
The effects of nicotine on ethanol-induced conditioned taste aversions in Long-Evans rats.
Psychopharmacology (Berl)
; 197(3): 409-19, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18204997
19.
An assessment of sex differences in nicotine-induced conditioned taste aversions.
Pharmacol Biochem Behav
; 88(4): 427-31, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17945339
20.
Strain-dependent sex differences in the effects of alcohol on cocaine-induced taste aversions.
Pharmacol Biochem Behav
; 83(4): 554-60, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16650466